We recently reported that the SGLT2 inhibitor dapagliflozin improves hepatic steatosis in patients with type 2 diabetes and NAFLD, and attenuates liver fibrosis in patients with significant fibrosis [11], suggesting that SGLT2 inhibitors have an anti-fibrotic effect on human NASH. Here, SLC5A2 is linked to Hepatic steatosis.